<DOC>
	<DOCNO>NCT03081247</DOCNO>
	<brief_summary>This 12-week chronic-dosing study assess efficacy safety BGF MDI compare BFF MDI subject moderate severe COPD .</brief_summary>
	<brief_title>To Assess Efficacy Safety PT010 Compared PT009 Subjects With Moderate Very Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , parallel-group , 12-week chronic-dosing study assess efficacy safety BGF MDI compare BFF MDI subject moderate severe COPD . The study total 7 visit Screening Period 28 day Treatment Period 12 week follow telephone follow-up call 14 day last dose study drug .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Key Signed Informed Consent Subjects establish clinical history COPD Forced expiratory volume 1 second ( FEV1 ) /Forced vital capacity ( FVC ) ratio must &lt; 0.70 FEV1 must &lt; 80 % predict normal value All subject must 2 inhaled maintenance therapy management COPD least 6 week prior Screening Current former smoker history least 10 packyears cigarette smoke Women Nonchildbearing potential Women childbearing potential sexually active agree prevent pregnancy use acceptable contraceptive method consistently Key Significant diseases condition COPD , opinion Investigator , may put subject risk participation study may influence either result study subject 's ability participate study Women pregnant lactating , plan become pregnant course study , woman childbearing potential use acceptable method contraception Current diagnosis asthma Uncontrolled sleep apnea Other Serious Respiratory Disorders Hospitalized due poorly control COPD within 6 week Poorly Controlled COPD Immune deficiency and/or severe neurological disorder affect control upper airway Hypersensitivity Î²2agonists , corticosteroid , muscarinic anticholinergic</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>